|
As On 17-Jul-18
|
|
Adf Foods
|
|
|
|
Adf Foods Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
|
|
|
Ajanta Pharma
|
|
|
|
On BSE's website, it is mentioned that BSE has sought clarification from the company with respect to news article appearing on hindi.moneycontrol.com - July 12, 2018 titled "Drug Controller''s Action on Ajanta Pharma". However, we have not received any letter/e-mail from BSE in this regard. Nonetheless, we are giving below the clarification on the news item, which we have submitted to NSE: 1. There is no action against Ajanta Pharma Ltd. from the office of Drug Controller General of India and we refute the allegations made against the company in the said article. 2. The action is taken against M/s. Safetab Life Sciences, who is the manufacturer of drugs. We are only marketing the drugs. 3. There is no impact of this article on the Company as Ajanta Pharma Ltd. is fully compliant with all the applicable regulatory requirements. 4. Since this would have no bearing on the performance or operations of the Company, the same is not required to be disclosed under Regulation 30 of the Listing Regulations, hence not disclosed. We hope above clarifies the position.
|
|
|
Auto.axle
|
|
|
|
With reference to SEBI, circular No: SEBI/HO/MIRSD/DOP1/CIR/P/2018/73 dated April 20, 2018, has mandated all listed Companies to update the Permanent Account Number (PAN) and Bank account details of the shareholders. A letter communication was sent to the shareholders as enclosed. Kindly take the same on record.
|
|
|
Bajaj Steel Inds.
|
|
|
|
Sub : Resignation of Dr. Panna Akhani as an Independent Director In terms of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we hereby inform you that the company has received the resignation of Dr. Panna Akhani designated as an Independent Director of the company due to the personal reasons on 16th July 2018. This is for your information and record purposes.
|
|
|
Bf Investment
|
|
|
|
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we would like to inform you that Mr. Hrushikesh S. Kulkarni, Chartered Accountant (Membership No.160187), Independent Auditor of the Company, who was appointed for a period of five years to hold office from the conclusion of 8th Annual General Meeting (AGM) untill the conclusion of 13th AGM has informed, vide his letter dated July 16, 2018, his inability to continue as Independent Auditor of the Company due to challenges in retaining required manpower, particularly in the light of the implementation of Ind-AS framework with effect from April 1, 2018, thereby putting constraints in meeting stringent timelines, with effect from the conclusion of ensuing 9th AGM of the Members of the Company. We request you to kindly take the above information on record.
|
|
|
Bharat Financial Inc
|
|
|
|
The Company has allotted today, 62,764 equity shares of Rs.10/- each to the employees of the Company who have exercised options under various Stock Option Plans. The said shares shall rank pari-passu with the existing equity shares of the Company in all respects.
|
|
|
Blue Star
|
|
|
|
Press Release - Blue Star wins prestigious Engineering Facility Management (EFM) orders from Airport and Metro segments
|
|
|
Cadila Healthcare
|
|
|
|
Zydus receives final approval from the USFDA for Clindamycin Phosphate Topical Solution USP
|
|
|
Crisil
|
|
|
|
Inter alia, the Board of Directors has also approved the payment of Second Interim dividend of Rs. 6 per equity share of face value of Re 1 each, for the financial year ending December 31, 2018, which will be paid on August 7, 2018. The company has informed that after serving for a decade, Dr. Nachiket Mor will be completing his tenure as Independent Director of CRISIL on July 23, 2018 and will cease to be a Director on CRISIL s Board post this date.
|
|
|
Crisil
|
|
|
|
Kindly be informed that the Board of Directors of the Company, at their meeting held today, has approved the Unaudited Standalone and Consolidated Financial Results for the second quarter ended June 30, 2018. A copy of the Unaudited Financial Results of the Company, along with a copy of the Limited Review Report and the Press Release in this regard are enclosed. The Board of Directors has also approved the payment of Second Interim dividend of Rs. 6 per equity share of face value of Re 1 each, for the financial year ending December 31, 2018, which will be paid on August 7, 2018. We also wish to inform you that after serving for a decade, Dr. Nachiket Mor will be completing his tenure as Independent Director of CRISIL on July 23, 2018 and will cease to be a Director on CRISIL's Board post this date. The meeting of the Board of Directors commenced at 9.30 a.m. IST and concluded at 5.45 p.m. IST today. Kindly take this communication on record and inform your members accordingly.
|
|
|
|
|
|
|
|
|